title: Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
authors.affiliation: Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
authors.forename: John S
authors.initials: JS
authors.lastname: Yi
authors.forename: Emily C
authors.initials: EC
authors.lastname: Decroos
authors.forename: Donald B
authors.initials: DB
authors.lastname: Sanders
authors.forename: Kent J
authors.initials: KJ
authors.lastname: Weinhold
authors.forename: Jeffrey T
authors.initials: JT
authors.lastname: Guptill
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D018941:Antigens, CD19 / Q000378:metabolism; D001402:B-Lymphocytes / Q000473:pathology*; D002452:Cell Count; D005229:Fatty Acids, Monounsaturated / Q000276:immunology; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000209:etiology*; D007155:Immunologic Factors / Q000009:adverse effects*; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000276:immunology; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19; D005229:Fatty Acids, Monounsaturated; D007155:Immunologic Factors; C008563:musk; D000069283:Rituximab